Cohort Studyhigh evidence
Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias.
Nature aging·July 20, 2026·PMID 42477094
Why it mattersDifferential diagnosis of neurodegenerative dementias remains challenging, especially in early stages. A blood-based proteomic panel could provide a scalable, objective tool to distinguish Alzheimer's disease, Lewy body dementia, and frontotemporal dementia, potentially improving diagnostic accuracy and enabling earlier, more targeted management.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled